RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Telix Pharmaceuticals Stock

Telix Pharmaceuticals Stocks 2025

Telix Pharmaceuticals Stocks

345.19 M

Ticker

TLX.AX

ISIN

AU000000TLX2

WKN

A2H7JK

In 2025, Telix Pharmaceuticals had 345.19 M outstanding stocks, a 0% change from the 345.19 M stocks in the previous year.

The Telix Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (M AUD)
2030e345.19
2029e345.19
2028e345.19
2027e345.19
2026e345.19
2025e345.19
2024345.19
2023323.71
2022310.64
2021282.21
2020257.27
2019233.44
2018202.12
2017127.99

Telix Pharmaceuticals shares outstanding

The number of shares was Telix Pharmaceuticals in 2024 — This indicates how many shares 345.188 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Telix Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Telix Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Telix Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Telix Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Telix Pharmaceuticals Aktienanalyse

What does Telix Pharmaceuticals do?

Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Telix Pharmaceuticals's Shares Outstanding

Telix Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Telix Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Telix Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Telix Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Telix Pharmaceuticals stock

How many stocks are there of Telix Pharmaceuticals?

The current number of stocks of Telix Pharmaceuticals is 345.19 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Telix Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Telix Pharmaceuticals evolved in recent years?

The number of shares of Telix Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Telix Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Telix Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Telix Pharmaceuticals pay?

Over the past 12 months, Telix Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Telix Pharmaceuticals is expected to pay a dividend of 0 AUD.

What is the dividend yield of Telix Pharmaceuticals?

The current dividend yield of Telix Pharmaceuticals is .

When does Telix Pharmaceuticals pay dividends?

Telix Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Telix Pharmaceuticals?

Telix Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Telix Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Telix Pharmaceuticals located?

Telix Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Telix Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Telix Pharmaceuticals from 10/9/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/9/2025.

When did Telix Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/9/2025.

What was the dividend of Telix Pharmaceuticals in the year 2024?

In the year 2024, Telix Pharmaceuticals distributed 0 AUD as dividends.

In which currency does Telix Pharmaceuticals pay out the dividend?

The dividends of Telix Pharmaceuticals are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Telix Pharmaceuticals

Our stock analysis for Telix Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Telix Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.